^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TargomiR (EGFREDVmiR-16)

    i
    Associations
    News

    Trials

    Company:
    Asbestos Diseases Research Institute, EnGeneIC
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC (NCT02369198)
    Phase 1
    Asbestos Diseases Research Foundation
    Completed
    Last update posted :
    04/07/2017
    Initiation :
    09/01/2014
    Primary completion :
    01/04/2017
    Completion :
    01/04/2017
    EGFR
    |
    EGFR expression
    |
    TargomiR (EGFREDVmiR-16)